Company / Gross Profit
ELITE PHARMACEUTICALS INC /NV/ Gross Profit History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Profit
$40.1M
FY2024
5-year range
$14.8M / $40.1M
FY2020-FY2024
Trend
+52.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Gross Profit has increased for 6 consecutive years, from $3M in FY2018 to $40M in FY2024.
Based on SEC 10-K filings.
$40M in FY2024 with a 5-year CAGR of +38.1%.
Improved from $17M to $40M over the past 2 years.
Gross Profit over time
Growth rates
- 3-Year CAGR
- +39.4%
- 5-Year CAGR
- +38.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- ELITE PHARMACEUTICALS INC /NV/'s gross profit has grown for 6 consecutive years.
- 5-year CAGR of +38.1%, indicating consistent growth.
- In FY2024, gross profit increased 52.1% year-over-year.
- Lowest gross profit in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross ProfitValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $40.1M | +52.1% |
| FY2023 | $26.4M | +58.8% |
| FY2022 | $16.6M | +12.2% |
| FY2021 | $14.8M | +24.7% |
| FY2020 | $11.9M | +48.7% |
| FY2019 | $8.0M | +178.2% |
| FY2018 | $2.9M | -27.4% |
| FY2017 | $3.9M | +5.6% |
| FY2016 | $3.7M | -53.3% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026